NeurogesX Expands Commercial Operations Leade...( SAN MATEO Calif. Nov. 5 /- NeurogesX ...),Health

SAN MATEO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the expansion of its U.S. commercial operations team to include a Vice President of Sales, Senior Director of Marketing and Director of Commercial Operations.

• Timothy Arendt has been named Vice President Sales. He will implement and manage the U.S. specialty sales force for Qutenza(TM).
  

• Amy C. Cavers has joined NeurogesX as Senior Director of Marketing. She will be responsible for U.S. marketing and the development of physician, payer and patient strategies to support the anticipated launch of Qutenza.
  

• Linda L. Schock has been appointed Director of Commercial Operations. She will play a critical role in creating commercial infrastructure and processes for the Qutenza launch, including establishing and managing distribution channels.
  

Anthony DiTonno, President and CEO, commented, "With our PDUFA date fast approaching, this is a truly exciting time at NeurogesX as we gear up for the potential U.S. commercial launch of Qutenza. Each of these new commercial team members has exceptional, highly relevant experiences that provide a wonderful complement to our strong NeurogesX team. These individuals are joining Christopher Panarites, Senior Director of Reimbursement, to round out our commercial operations management team under Michael Markels, our Vice President of Commercial Operations and Business Development. They will all be instrumental in helping us execute a successful U.S. launch of Qutenza."

Mr. Arendt has 20 years of pharmaceutical marketing and sales experience. Prior to his arrival at NeurogesX, Mr. Arendt was Vice President, Sales at Xanodyne
'/>"/>